Acute myeloid leukaemia: NICE approves liposomal cytarabine-daunorubicin

  • Dawn O'Shea
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has approved liposomal cytarabine-daunorubicin (Vyxeos) as an option for recently-diagnosed untreated therapy-related acute myeloid leukaemia (AML) and AML with myelodysplasia-related changes in adults.

The decision is based on evidence from the phase 3, multicentre, open-label, randomised Study 301 which included 309 adults aged 60-75 years with high-risk AML.

Treatment with liposomal cytarabine-daunorubicin was associated with increased median overall survival (OS) compared with standard cytarabine and daunorubicin (HR 0.69; 95% CI 0.52-0.90; P=0.005). Median OS was 9.56 months and 5.95 months, respectively.

A post-hoc analysis of the data showed 52 people in the liposomal cytarabine-daunorubicin group and 39 people in the comparator group received a stem cell transplant. In this subgroup, median OS was 10.25 months in the standard cytarabine and daunorubicin group and was not reached in the liposomal cytarabine-daunorubicin group (HR 0.46; 95% CI 0.24-0.89; P=0.0046).

The treatment is administered by intravenous infusion over 90 minutes. For induction of remission, the regimen is daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 on days 1, 3, and 5 for the first course and on days 1 and 3 for subsequent courses, if needed.

For consolidation (5 to 8 weeks after the start of induction), the regimen is daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 on days 1 and 3. A subsequent course of consolidation may be given when there is no disease progression or unacceptable toxicity.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.